Thomas Kelleher

557 total citations
11 papers, 380 citations indexed

About

Thomas Kelleher is a scholar working on Infectious Diseases, Virology and Emergency Medicine. According to data from OpenAlex, Thomas Kelleher has authored 11 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 5 papers in Virology and 3 papers in Emergency Medicine. Recurrent topics in Thomas Kelleher's work include HIV/AIDS drug development and treatment (6 papers), HIV Research and Treatment (5 papers) and HIV-related health complications and treatments (3 papers). Thomas Kelleher is often cited by papers focused on HIV/AIDS drug development and treatment (6 papers), HIV Research and Treatment (5 papers) and HIV-related health complications and treatments (3 papers). Thomas Kelleher collaborates with scholars based in United States, Germany and Argentina. Thomas Kelleher's co-authors include Pedro Cahn, Michael Giordano, Robert L. Murphy, Praphan Phanuphak, Anne Cross, Lisa M. Dunkle, Marco Mancini, Vadim Pokrovskiy, Michael Sension and Robin Wood and has published in prestigious journals such as The Lancet, Annals of Oncology and AIDS.

In The Last Decade

Thomas Kelleher

11 papers receiving 356 citations

Peers

Countries citing papers authored by Thomas Kelleher

Since Specialization

Citations

This map shows the geographic impact of Thomas Kelleher's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Kelleher with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Kelleher more than expected).

Fields of papers citing papers by Thomas Kelleher

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Kelleher. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Kelleher. The network helps show where Thomas Kelleher may publish in the future.

Co-authorship network of co-authors of Thomas Kelleher

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Kelleher. A scholar is included among the top collaborators of Thomas Kelleher based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Kelleher. Thomas Kelleher is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	Model-based assessment of benefit-risk profile of nivolumab (NIVO) flat dosing schedules (Q2W and Q4W) across multiple tumor types 2018 ·Annals of Oncology ·Xiaochen Zhao, Jun Shen, Mathangi Gopalakrishnan, Feng Yan, Brian J. Schmidt, Paul Statkevich, Thomas Kelleher, Michelle Rashford, Vijay Ivaturi, Jogarao Gobburu, Sachin Agrawal, Akintunde Bello, Amit Roy	3
2	Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies 2010 ·Breast Cancer Research and Treatment ·Henri Roché, Pierfranco Conté, Edith A. Perez, Joseph A. Sparano, Binghe Xu, Jacek Jassem, Ronald Peck, Thomas Kelleher, Gabriel N. Hortobágyi	19
3	Long-Term Efficacy and Safety of Atazanavir With Stavudine and Lamivudine in Patients Previously Treated With Nelfinavir or Atazanavir 2004 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Robin Wood, Praphan Phanuphak, Pedro Cahn, Vadim Pokrovskiy, Willy Rozenbaum, Giuseppe Pantaleo, Michael Sension, Robert L. Murphy, Marco Mancini, Thomas Kelleher, Michael Giordano	74
4	Atazanavir—A Once-daily HIV Protease Inhibitor That Does Not Cause Dyslipidemia in Newly Treated Patients: Results from Two Randomized Clinical Trials 2004 ·Journal of the International Association of Physicians in AIDS Care ·Pedro Cahn, José M. Gatell, Kathleen Squires, (unknown), Peter J. Piliero, (unknown), Sarah Shelton, Adriano Lazzarin, (unknown), Thomas Kelleher, Alexandra Thiry, Michael Giordano, (unknown)	50
5	Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naive subjects 2003 ·AIDS ·Robert L. Murphy, (unknown), Pedro Cahn, Praphan Phanuphak, (unknown), Thomas Kelleher, Michael Giordano	166
6	Missing Data Methods in HIV Clinical Trials: Regulatory Guidance And Alternative Approaches 2001 ·Drug Information Journal ·Thomas Kelleher, Alexandra Thiry, Richard B. Wilber, Anne Cross	1
7	Relation of peripheral neuropathy to HIV treatment in four randomized clinical trials including didanosine 1999 ·Clinical Therapeutics ·Thomas Kelleher, Anne Cross, Lisa M. Dunkle	30
8	Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine 1999 ·AIDS ·(unknown), Richard B. Pollard, Shannon Schrader, (unknown), Thomas Kelleher, C. McLaren	22
9	The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection 1999 ·Clinical Therapeutics ·Richard Elion, Sanjeev Kaul, Catherine Knupp, (unknown), Anne Cross, Lisa M. Dunkle, Thomas Kelleher	3
10	A bayes method for estimating the common mean of two normal populations 1996 ·Communication in Statistics- Theory and Methods ·Thomas Kelleher	6
11	AGRANULOCYTOSIS DURING ISONIAZID THERAPY 1953 ·The Lancet ·S. Varadi, Thomas Kelleher	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact